In two trials of linaclotide, about 21 percent of participants with chronic constipation had at least three spontaneous bowel movements a week, compared with no more than 6 percent taking a placebo.
The drug, a minimally absorbed peptide agonist of the guanylate cyclase C receptor, also helped reduce abdominal discomfort, bloating and the severity of constipation.
Read the New England Journal of Medicine report on the drug linaclotide for chronic constipation.
Related Articles on Constipation:
25-50% of Older Americans Experience Pain, Many Untreated
Henry Ford Hospital: Pill Reduces Prep Needed for Colonoscopy
Rome Foundation Releases New Tool for Diagnosis of Common GI Symptoms
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.